Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.25 +1.2%	$0.27	$0.20 ▼ $1.48	$64.19M	2.24	1.68 million shs	936,666 shs
ANRO Alto Neuroscience	$2.35 +2.0%	$2.47	$1.60 ▼ $17.55	$62.27M	1.93	412,404 shs	2.61 million shs
MNOV MediciNova	$1.33 +2.3%	$1.42	$1.12 ▼ $2.55	$63.76M	0.42	36,039 shs	15,976 shs
MRKR Marker Therapeutics	$1.46	$1.33	$0.95 ▼ $5.99	$16.52M	1.44	79,860 shs	69,446 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+1.16%	-3.16%	-9.63%	+18.93%	-70.54%
ANRO Alto Neuroscience	+1.74%	+5.63%	-13.94%	+1.74%	-76.46%
MNOV MediciNova	+2.31%	+3.10%	-6.34%	-8.28%	-6.99%
MRKR Marker Therapeutics	0.00%	+0.69%	+32.73%	+14.96%	-69.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.1999 of 5 stars	4.1	5.0	0.0	2.2	0.8	0.0
ANRO Alto Neuroscience	2.3329 of 5 stars	3.3	2.0	0.0	2.3	0.8	1.3
MNOV MediciNova	1.9803 of 5 stars	3.8	2.0	0.0	2.2	0.8	0.0
MRKR Marker Therapeutics	4.2241 of 5 stars	3.8	3.0	3.9	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	451.70% Upside
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	262.47% Upside
MNOV MediciNova	3.50	Strong Buy	$7.00	426.32% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	801.83% Upside

Current Analyst Ratings Breakdown

Latest MRKR, MNOV, ADAP, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/16/2025	MNOV MediciNova	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$6.00 ➝ $5.00
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/9/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.36	N/A	N/A	$0.05 per share	4.90
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
MNOV MediciNova	$1M	65.24	N/A	N/A	$1.07 per share	1.24
MRKR Marker Therapeutics	$6.59M	2.51	N/A	N/A	$1.73 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
ANRO Alto Neuroscience	-$61.43M	-$2.34	N/A	N/A	N/A	N/A	-39.35%	-33.86%	8/12/2025 (Estimated)
MNOV MediciNova	-$11.04M	-$0.23	N/A	N/A	N/A	N/A	-20.77%	-19.68%	8/6/2025 (Estimated)
MRKR Marker Therapeutics	-$10.73M	-$1.33	N/A	N/A	N/A	-224.46%	-101.87%	-83.02%	8/13/2025 (Estimated)

Latest MRKR, MNOV, ADAP, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/13/2025	Q1 2025	MNOV MediciNova	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
ANRO Alto Neuroscience	0.15	22.53	22.53
MNOV MediciNova	N/A	17.66	17.66
MRKR Marker Therapeutics	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
ANRO Alto Neuroscience	N/A
MNOV MediciNova	9.90%
MRKR Marker Therapeutics	22.39%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
ANRO Alto Neuroscience	11.13%
MNOV MediciNova	13.60%
MRKR Marker Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	24.06 million	N/A
MNOV MediciNova	10	49.05 million	42.38 million	Optionable
MRKR Marker Therapeutics	60	11.31 million	9.67 million	Not Optionable

MRKR, MNOV, ADAP, and ANRO Headlines

Recent News About These Companies

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

June 17, 2025 | globenewswire.com

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025 | globenewswire.com

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025 | globenewswire.com

Arkansas Historic Preservation Program hosts National Historic Marker Weekend

April 17, 2025 | stuttgartdailyleader.comS

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

April 1, 2025 | globenewswire.com

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

March 31, 2025 | markets.businessinsider.com

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

March 31, 2025 | globenewswire.com

Marker Therapeutics stockholder vote clears warrant issuance

March 28, 2025 | investing.com

Marker Therapeutics initiated with a Buy at Canaccord

March 5, 2025 | markets.businessinsider.com

Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation

March 5, 2025 | msn.com

Marker Therapeutics, Inc. CEO Juan Vera to Present at H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | quiverquant.comQ

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | globenewswire.com

MRKR stock touches 52-week low at $1.61 amid market challenges

February 12, 2025 | msn.com

Brookline Capital sets $4 target on Marker Therapeutics stock

February 11, 2025 | msn.com

Marker Therapeutics initiated with a Buy at Brookline

February 11, 2025 | markets.businessinsider.com

MRKR stock touches 52-week low at $1.8 amid market challenges

January 31, 2025 | msn.com

Marker Therapeutics Announces Board Resignation

January 31, 2025 | msn.com

MRKR stock touches 52-week low at $2.4 amid challenging year

January 21, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, MNOV, ADAP, and ANRO Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.24 +0.00 (+1.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.25 +0.00 (+0.82%)

As of 06/27/2025 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Alto Neuroscience NYSE:ANRO

$2.35 +0.05 (+1.96%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$2.39 +0.04 (+1.88%)

As of 06/27/2025 06:46 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

MediciNova NASDAQ:MNOV

$1.32 +0.02 (+1.92%)

As of 06/27/2025 04:00 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Marker Therapeutics NASDAQ:MRKR

$1.47 +0.01 (+0.41%)

As of 06/27/2025 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time